Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available.
The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens.
The Nipah and Hendra viruses are members of the genus Henipavirus, a new class of virus in the Paramyxoviridae family, which includes the measles and the human parainfluenza virus (HPIV) that causes pediatric respiratory disease. The henipaviruses are carried by fruit bats (flying foxes) and are capable of causing illness and death in domestic animals and humans.
"These viruses are of great concern. The Hendra virus is highly fatal and is a considered a potential agent of bioterrorism. It currently poses a serious threat to livestock in Australia, where sporadic and deadly transmission to humans has occurred, with the potential for broader dissemination," says Dr. Matteo Porotto, the study's lead author and assistant professor of microbiology in pediatrics at Weill Cornell Medical College. "And the Nipah virus, which causes fatal encephalitis in up to 70 percent of human cases, causes seasonal outbreaks in Asia with person-to-person transmission now becoming a primary mode of infection. This virus could certainly cause global outbreaks."
Dr. Porotto and colleagues present a new strategy to prevent and treat these infections that may be broadly applicable for other "enveloped" viral pathogens, characterized by an outer wrapping that comes from the infected host cell. The new treatment was successfully tested in an animal model demonstrating central nervous system symptoms similar to those seen in humans.
Dr. Anne Moscona, professor of pediatrics and microbiology & immunology at Weill Cornell Medical College, vice chair of pediatrics for research at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, chief of pediatric infectious diseases and co-corresponding author of the paper, says, "It's crucial that we find treatments for the Nipah and Hendra viruses. In addition to acute infection, they can cause asymptomatic infection in as many as 60 percent of exposed people. They may also lead to late-onset disease or relapse of encephalitis years after initial infection, as well as persistent or delayed neurological problems."
According to Dr. Porotto, it is difficult to treat these pathogens because their "envelope" helps the virus survive and infect other cells. "We know that enveloped viruses must fuse their membrane with the target cell membrane in order to initiate infection, and blocking this step can prevent or treat infection, as has been clinically validated for the HIV virus."
Building on their past work, the team demonstrated in this study that the addition of a cholesterol group to HRC peptides that are active against Nipah virus dramatically increases their antiviral effect. The approach works by using the cholesterol-tagged peptides to target the membrane where the fusion occurs. There, the peptides interact with the fusion peptide before it inserts into the target cell membrane, disrupting the crucial membrane fusion process and preventing infection.
"The cholesterol-tagged HRC-derived peptides cross the blood-brain barrier and help prevent and treat the infection in animals for what would otherwise be fatal Nipah virus encephalitis," Dr. Porotto reports. "This suggests that they are promising candidates for the prevention or therapy of infection by Nipah and other lethal paramyxoviruses and may lead to better treatments for people affected by similar viruses including the measles, mumps and the flu."
Additional co-authors include Christine C. Yokoyama, Aparna Talekar, Ilaria DeVito, Laura M Palermo and Min Lu from Weill Cornell Medical College; Barry Rockx and Heinz Feldmann from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT; Riccardo Cortese from CEINGE, Naples, Italy; and Antonello Pessi from PeptiPharma, Rome, Italy.
Weill Cornell Medical College
Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston, making Weill Cornell one of only two medical colleges in the country affiliated with two U.S.News & World Report Honor Roll hospitals. For more information, visit www.med.cornell.edu.
Andrek Klein | EurekAlert!
Signaling Pathways to the Nucleus
19.03.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau
In monogamous species, a compatible partner is more important than an ornamented one
19.03.2018 | Max-Planck-Institut für Ornithologie
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News